[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354830-105":59,"doc-detail-354830-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","broadening-the-gates-analysis-of-potentially-modifiable-study-entry-criteria-in-pancreatic-and-biliary-tract-cancer-trials","Broadening the gates - Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials","","Eligibility criteria for cancer clinical trials are essential for participant safety and study validity, yet restrictive requirements can produce unrepresentative populations. A retrospective analysis evaluated screen-failed consenters with pancreatic or biliary tract cancer at MD Anderson (Aug 2019-Nov 2024), identifying potentially modifiable exclusions. From 509 analyzed patients across 18 trials, major failure causes were declined participation, comorbidities, organ-function limits, absent biomarkers, and insufficient biospecimens, with PMEs found in 69 patients. Results support easing incidental lab abnormalities to improve enrollment without compromising safety.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/broadening-the-gates-analysis-of-potentially-modifiable-study-entry-criteria-in-pancreatic-and-biliary-tract-cancer-trials/354830/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/broadening-the-gates-analysis-of-potentially-modifiable-study-entry-criteria-in-pancreatic-and-biliary-tract-cancer-trials/354830.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What issue does the study address about eligibility criteria in cancer trials?","Question",{"text":113,"@type":114},"The study examines how overly restrictive eligibility criteria can exclude real-world patients, reducing representativeness and potentially creating gaps in understanding treatment effectiveness.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were potentially modifiable exclusions (PMEs) identified in the study?",{"text":118,"@type":114},"PMEs were identified and validated by two independent medical oncologists based on screening logs and electronic health records for screen-failed patients who had provided informed consent.",{"name":120,"@type":111,"acceptedAnswer":121},"What types of factors commonly led to screen failure and what role did PMEs play?",{"text":122,"@type":114},"Common screen failure causes included declined participation, comorbidities, suboptimal organ function, lack of biomarkers, and insufficient biospecimens. PMEs were found in 69 patients, largely driven by borderline laboratory abnormalities such as liver and kidney function, platelet count, hemoglobin, and white blood cell count.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354830,1790795826,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":19,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","DOI: 10. 1002/cncr.70227  \nORIGINAL ARTICLE  \nBroadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials  \nFen Saj MD, DM 1 | Felicity K. Namayanja MBChB, MPH 1 | Lianchun Xiao MS2  | Mitesh J Borad MD3 | Robin Kate Kelley MD4  | Lipika Goyal MD, MPhil5  | Nilofer S. Azad MD6 | Melinda Bachini7,8  | Stacie Lindsey BA7,8 |  \nShubham Pant MD 1  | Juan W. Valle MBChB, MSc, FRCP7,8 | Lola A Fashoyin-Aje MD, MPH9 | Milind Javle MD 1   \n1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA  \n3Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Scottsdale, Arizona, USA  \n4Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California, USA 5Department of Medicine, Division of Hematology and Oncology, Stanford Cancer Center, Palo Alto, California, USA  \n6Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 7The Cholangiocarcinoma Foundation, Herriman, Utah, USA  \n8Division of Cancer Sciences, University of Manchester, Manchester, UK  \n9Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland, USA  \nCorrespondence  \nMilind Javle, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX  \n77030, USA.  \n[Email:](Email: mjavle@mdanderson.org)[ mjavle@mdanderson.org](Email: mjavle@mdanderson.org)  \nAbstract  \nBackground: Eligibility criteria for clinical trials are crucial for maintaining safety and study integrity. However, overly restrictive criteria can result in unrepresentative trial populations, leading to gaps in understanding real-world treatment efficacy. Addressing potentially modifiable exclusions (PMEs) could enhance trial accessibility and participation without compromising safety.  \nMethods: The authors retrospectively analyzed screen-failed patients with biliary tract cancer or pancreatic cancer between August 2019 and November 2024 at The University of Texas MD Anderson Cancer Center. Screen-failed patients were those who provided informed consent but did not participate for any reason. Clinical data were obtained from screening logs and electronic health records. PMEs were identified and validated by two independent medical oncologists.  \nResults: Of 585 screen-failed patients from 18 trials, 509 were analyzed (367 with pancreatic cancer and 142 with biliary tract cancer) after excluding 76 because of incomplete data. Leading causes of screen failure were declined participation (19%),  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2025 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer. 2026;e70227.  \n[https://doi.org/10.1002/cncr.70227](https://doi.org/10.1002/cncr.70227)  \nwi[leyonlinelibrary.com/journal/cncr](leyonlinelibrary.com/journal/cncr)  \n1 of 8  \ncomorbidities (12%), suboptimal organ function (11%), absence of a biomarker (10%), and insufficient biospecimens (7%). Reasons for declining included preference for standard care (23%), travel (22%), and competing trials (5%). The authors identified 69 patients (13.6%) who had PMEs (primarily borderline laboratory abnormalities), including liver function (23%), kidney function (20%), platelet count (12%), hemoglobin (7%), and white blood cell count (6%) abnormalities. Other PMEs included previous or concurrent malignancies (9%) and viral hepa","cbCaipFc86cBEQ71","https://ap.wps.com/l/cbCaipFc86cBEQ71","pdf",355538,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What issue does the study address about eligibility criteria in cancer trials?\",\"answer\":\"The study examines how overly restrictive eligibility criteria can exclude real-world patients, reducing representativeness and potentially creating gaps in understanding treatment effectiveness.\"},{\"question\":\"How were potentially modifiable exclusions (PMEs) identified in the study?\",\"answer\":\"PMEs were identified and validated by two independent medical oncologists based on screening logs and electronic health records for screen-failed patients who had provided informed consent.\"},{\"question\":\"What types of factors commonly led to screen failure and what role did PMEs play?\",\"answer\":\"Common screen failure causes included declined participation, comorbidities, suboptimal organ function, lack of biomarkers, and insufficient biospecimens. PMEs were found in 69 patients, largely driven by borderline laboratory abnormalities such as liver and kidney function, platelet count, hemoglobin, and white blood cell count.\"}]","Broadening the gates - Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials | PDF",1790114311,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/388b2694e78d1522884ec0d0759611bc.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df669e5d782684ae7a6b40eea4a49417.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f84b1df67c3a4e69343c752fb35deeb.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb01a6710fd3a0ec0e38467c1660bde0.webp",980,1287]